France Infectious Disease Therapeutics Market Analysis

France Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the France infectious disease therapeutics market will reach a value of $4.29 Bn from $3.3 Bn in 2022, growing at a CAGR of 3.4% during 2022-2030.

France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. Among the infectious diseases in France, widespread ongoing transmission of a respiratory illness caused by the novel coronavirus (COVID-19) was occurring throughout France; as of December 2022, France has reported a total of 37,252,086 cases of COVID-19. the French National Authority for Health (HAS), which provides guidance on the use of new treatments within the healthcare system. France offers universal healthcare, which covers 77.4 % of healthcare costs. The remainder of the payments are either out-of-pocket or covered by volunteer health insurance. France's government spends 12.2 % of its GDP on healthcare in 2020.

Market Dynamics

Market Growth Drivers Analysis

Significant investment has been made in the research and development of infectious disease medicines in France, particularly in the areas of antibiotic resistance, HIV/AIDS, and hepatitis C. In France, two organisations are actively participating in infectious disease treatment research: the French National Institute of Health and Medical Research (INSERM) and the French Agency for Research on AIDS and Viral Hepatitis (ANRS). Several advances in infectious illness therapies have occurred in France in recent years. For example, various novel antiviral medications have been developed to treat hepatitis C, including sofosbuvir and ledipasvir.

In addition, novel antibiotics, such as ceftazidime-avibactam, have been developed to fight antibiotic-resistant infections. France has a talented and productive workforce, as well as a changing demography. The quality of infrastructure and public service facilities improves the country's corporate operations. These aspects could boost France's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and therapies necessitates adhering to regulatory rules established by organisations such as the French National Agency for Medicines and Health Products Safety (ANSM). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Drug companies may be hesitant to engage in researching novel medicines if they fear the end result will be unprofitable due to a lack of patent protection or competition from generic pharmaceuticals. These factors may deter new entrants into the France infectious disease therapeutics market.

Competitive Landscape

Key Players

• Sanofi - Sanofi is a leading French pharmaceutical company that develops and manufactures a range of infectious disease therapeutics, including vaccines, antibiotics, and antivirals
• Institut Mérieux - Institut Mérieux is a French biopharmaceutical company that specializes in the development and production of vaccines and immunotherapies
• BioMérieux - BioMérieux is a French biotechnology company that develops and manufactures diagnostic tests for infectious diseases
• Vaxxel - Vaxxel is a French biotechnology company that develops vaccines for infectious diseases. The company's lead product, a vaccine for pertussis (whooping cough), is currently in clinical trials
• Innate Pharma - Innate Pharma is a French biotechnology company that develops immunotherapies for cancer and infectious diseases

Recent Notable Updates

November 2022: Following the positive judgement of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on VidPrevtyn beta, the vaccine was authorised by the European Commission as a booster for the prevention of COVID-19 in adults aged 18 and over. Sanofi's VidPrevtyn Beta is a next-generation, monovalent, recombinant protein vaccine against COVID-19 based on the beta version and contains GSK's pandemic adjuvant.

Healthcare Policies and Reimbursement Scenarios

The National Agency for the Safety of Medicines (ANSM) and Health Products regulates infectious illness therapies in France. The ANSM is in charge of ensuring the safety, effectiveness, and high quality of all medications and medical equipment, particularly those used to treat infectious diseases. In order to be approved for use in France, infectious disease treatments must undergo a regulatory process that includes clinical studies and another testing to ensure their safety and efficacy. Following the approval of a product, the ANSM continues to monitor its safety and quality through post-marketing monitoring.

In France, the national health insurance system, known as the Assurance Maladie, manages the coverage of infectious disease medications. The cost of these therapies is either partially or completely reimbursed, depending on the patient's eligibility and the type of treatment. In France, the payment system is tier-based, with different levels of coverage depending on the severity of the sickness and the type of therapy necessary. Treatments for life-threatening infectious diseases like HIV or hepatitis C, for example, are often covered at a higher rate than treatments for less severe infections.